Optimization and Normalization Studies for Individual CSF Samples

单个 CSF 样本的优化和标准化研究

• 批准号: 9245119
• 负责人: JOSEPH F QUINN
• 金额: $ 7.3万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-08-01 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9245119
• 关键词: Age; Alzheimer' s Disease; Bioinformatics; Biological Assay; Biological Markers; Biometry; Bipolar Disorder; Brain Diseases; Brain Injuries; Caregivers; Case-Control Studies; Cause of Death; Cerebrospinal Fluid; Clinical; Clinical Research; Code; Complex; Data Set; Degenerative Disorder; Dementia; Diagnosis; Digestion; Disease; Disease Progression; Environment; Family; Gene Expression; Genes; Genomics; Goals; Health; Human; Impaired cognition; Individual; Ischemia; Liquid substance; Living Donors; Magnetic Resonance Imaging; Medical; Memory Loss; Mental disorders; Methodology; MicroRNAs; Molecular; Multiple Sclerosis; Oregon; Participant; Patients; Performance; Pharmaceutical Preparations; Plasma; Prognostic Marker; Progressive Disease; Psyche structure; Qualifying; Quality of life; Ribonucleoproteins; Risk Factors; Role; Sampling; Societies; Staging; Statistical Data Interpretation; Symptoms; Testing; Tissues; Traumatic Brain Injury; United States; Variant; age related; brain cell; clinical Diagnosis; cohort; design; diagnostic biomarker; differential expression; extracellular; human disease; member; mild cognitive impairment; multidisciplinary; neuroimaging; nuclease; population based; pre-clinical; preclinical study; sex; symptomatic improvement; tool

DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is the most common form of dementia and is the sixth leading cause of death in the United States. The greatest known risk factor for AD is increasing age; the majority of people with AD are age 65 and older. AD is a progressive disease, with dementia symptoms gradually worsening over several years. Current AD treatments cannot stop disease progression, but they can temporarily slow the progression of dementia symptoms and improve quality of life for those with AD and their caregivers. There is no diagnostic biomarker that can be used to predict the onset of AD, nor is there a biomarker which can distinguish early AD from age-related dementia. Such a discriminatory tool would be invaluable in guiding clinicians towards early interventional efforts. The existence of extracellular RNAs in biofluids represents a fertile molecular landscape from which diagnostic and prognostic biomarkers may be isolated, characterized, and exploited. Accordingly, the identification of extracellular RNAs in the cerebrospinal fluid (CSF) provides an opportunity to define important biomarkers for clinical use in characterizing dementias such as AD. MicroRNAs are members of the non-protein-coding family of RNAs that serve as regulators of post-transcriptional gene expression. MicroRNAs are increasingly being identified in circulating fluids such as CSF, plasma, serum, and placental tissue, where their expression is correlated with several diseases including brain injury, degenerative diseases, and mental health disorders. We propose to identify microRNAs in CSF to examine their utility as diagnostic biomarkers for AD. To achieve this goal, we have established a highly qualified, multidisciplinary investigative team with expertise AD, dementia, and CSF biomarkers, advanced genomic methodologies, biostatistics, and clinical studies to examine the clinical utility of microRNAs in CSF as diagnostic biomarkers for AD.

描述（由申请人提供）： 阿尔茨海默氏病（AD）是痴呆症的最常见形式，是美国第六大死亡原因。广告的最大风险因素是增加年龄。大多数AD患者的年龄较高65岁。 AD是一种进行性疾病，痴呆症症状在几年内逐渐恶化。当前的AD治疗不能阻止疾病的进展，但是它们可以暂时减慢痴呆症症状的进展并改善AD及其护理人员的生活质量。没有诊断生物标志物可以用于预测AD的发作，也没有可以将早期AD与年龄相关痴呆症区分开的生物标志物。这种歧视性工具对于指导临床医生进行早期介入的努力将是无价的。生物流体中细胞外RNA的存在代表 可以从中可以隔离，表征和利用肥沃的分子景观。因此，脑脊液（CSF）中细胞外RNA（CSF）的鉴定提供了定义重要的生物标志物来表征痴呆症（例如AD）的重要生物标志物。 MicroRNA是RNA的非蛋白质编码家族的成员，该家族是转录后基因表达的调节剂。在CSF，血浆，血清和胎盘组织等循环液中，越来越多地鉴定了microRNA，它们的表达与包括脑损伤，退行性疾病和精神健康疾病在内的多种疾病相关。我们建议识别CSF中的microRNA，以检查其效用作为AD的诊断生物标志物。为了实现这一目标，我们建立了一个具有专业知识AD，痴呆症和CSF生物标志物，高级基因组方法，生物统计学和临床​​研究的高素质，多学科的研究团队，以研究CSF作为AD诊断生物标志物的临床实用性。